These results showed that EZH2 and AURKA play an important role in promoting the proliferation, migration, and invasion of HCC, especially in TP53-mutant HCC, which indicates that they are potential targets for clinical therapy. This evidence concerns the gene EZH2 and hepatocellular carcinoma.